Method of treating metabolic disorders and depression with dopamine receptor agonists
This invention relates to methods and formulations for treating metabolic disorders and depression. In some embodiments, the methods comprise administering a dopamine receptor agonist and an anti-depressant.
1. A dosage form for administration to patients suffering from at least one of obesity, arteriosclerosis or coronary artery disease and also suffering from depression comprising a first active agent and a second active agent, wherein said first active agent is a serotonin enhancing agent, said second active agent is a dopamine agonist, said first active agent is substantially released within 2 hours following administration of said dosage form and said second active agent is released substantially within the period within 2 hours of waking when said dosage form is administered to said patients at bedtime.
2. The dosage form of claim 1 wherein the first active agent comprises an antidepressant.
3. The dosage form of claim 1 wherein the dopamine agonist is an ergot related dopamine D1 agonist.
4. The dosage form of claim 1 wherein the dopamine agonist is an ergot related dopamine D2 agonist.
5. The dosage form of claim 1 wherein the dopamine agonist is a DI dopamine agonist.
6. The dosage form of claim 1 wherein the dopamine agonist is a D2 dopamine agonist.
7. The dosage form of claim 5 wherein the DI dopamine agonist is SKF 38393.
8. The dosage form of claim 5 wherein the DI dopamine agonist is apomorphine.
9. The dosage form of claim 1 wherein the first active agent is a selective serotonin reuptake inhibitor.
10. The dosage form of claim 1 wherein the selective serotonin reuptake inhibitor is fluoxetine.
11. The dosage form of claim 6 wherein the D2 dopamine agonist is bromocriptine.
12. The method of treating a patient suffering from depression and at least one of obesity, arteriosclerosis or coronary artery disease which comprises administering to the patient a dosage form comprising a first active agent and a second active agent, wherein said first active agent is a serotonin enhancing agent, said second active agent is a dopamine agonist, said first active agent is substantially released within 2 hours following administration of said dosage form and said second active agent is released substantially within the period within 2 hours of waking when said dosage is administered to said patients at bedtime.
13. The method of claim 12 wherein the dopamine agonist is a D1 dopamine agonist.
14. The method of claim 12 wherein the dopamine agonist is a D2 dopamine agonist.
15. The method of claim 14 wherein the D2 dopamine agonist comprises bromocriptine.
16. The method of claim 13 wherein the D1 dopamine agonist is SKF38393.
17. The method of claim 13 wherein the D1 dopamine agonist is apomorphine.
18. The method of claim 12 wherein the serotonin enhancing agent is a selective serotonin reuptake inhibitor.